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Abstract The structural basis of opioid receptors (OPRs) for 
the subtype-selective binding of DAMGO, a p-opioid receptor 
selective ligand, was investigated using chimeric phc-OPRs. Re- 
placement of the region from the middle of the fifth transmem- 
brane domain to the C-terminal of p-OPR with the corresponding 
region of p-OPR remarkably decreased the binding affinity to 
DAMGO, while the reciprocal chimera revealed the high affinity 
to DAMGO. These results indicate that DAMGO distinguishes 
between p- and p-OPRs at the region around the third extracel- 
lular loop, different from the case of the distinction between 
p-and 8-OPRs in which the region around the first extracellular 
loop is important. Furthermore, displacement studies revealed 
that the region around the third extracellular loop is involved in 
the discrimination between p- and K-OPRs not only by peptidic 
p- selective ligands but also by non-peptidic ligands, such as 
morphine and naioxone. 
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1. Introduction 
Endogenous opioid peptides and opiate drugs like morphine 
act on the specific receptors expressing on cell surface to exert 
various physiological nd pharmacological effects, such as an- 
algesia, sedation, respiratory depression, euphoria nd modula- 
tion of neuroendocrine. The presence of at least three subtypes 
of opioid receptors (OPRs) in the nervous system has been 
established on the basis of differential pharmacological nd 
binding properties, i.e. Ft-, 6- and x-OPRs [1]. Although all of 
the three subtypes of OPRs couple via pertussis toxin-sensitive 
G proteins to various effectors including adenylate cyclase [2] 
and Ca 2+ and K ÷ channels [3] and many drugs act on the all 
subtypes, these subtypes can be discriminated using the ligands 
selective to each subtype. The structural basis for how those 
ligands discriminate among the three subtypes of OPRs is yet 
unknown and of great interest. 
Following the cloning of ~-OPR cDNA [4,5], we as well as 
several other groups cloned the cDNAs for/.t- and I¢-OPRs 
[6-8]. Hydropathy analyses of the deduced amino acid 
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sequences of these clones suggest hat these receptors have 
seven putative transmembrane h lices characteristic to G pro- 
tein- coupled receptors. Comparison of the amino acid se- 
quences of/l-, 6- and x-OPRs reveals that these receptors how 
an overall about 60% identity to one another. Higher identities 
are found in the transmembrane regions (73-76% of identities) 
and intracellular regions (63-66% of identities), while the ex- 
tracellular egions are considerably divergent (34-40% of iden- 
tities). It is likely that these divergent sequences are responsible 
for the discrimination among these subtypes by the subtype- 
selective opioid ligands. 
Cloning of the cDNAs for these OPRs has allowed to inves- 
tigate the structural basis for subtype specificity of the OPRs 
in their ligand bindings using the various molecular biological 
techniques. The construction of chimeric receptors is thought 
to be one of the very powerful approaches to the issue, as it has 
been demonstrated in the cases of adrenaline [9,10], ace- 
tylcholine [11], tachykinin [12,13] and endothelin [14] receptors. 
Recently, using chimeric /~/~-OPRs, we have shown that 
DAMGO, a/I-OPR selective ligand, distinguishes between H- 
and 6-OPRs at the region around the first extracellular loop 
and that this region is partly involved in the discrimination 
between/l- and ~-OPRs also by other several peptidic/~-selec- 
tive ligands, such as dermorphin, morphiceptin and CTOP, but 
not by non-peptidic ligands, such as morphine and naloxone 
[15]. In the present study, we constructed chimeric/l/x-OPRs 
and examined their binding characteristics to DAMGO and 
other several/.t-selective opioid ligands. We will show here that 
DAMGO distinguishes between ~t- and x-OPRs at the different 
region from that for the distinction between/1- and ~-OPRs, 
and that the region around the third extracellular loop is in- 
volved in the discrimination between jl- and x-OPRs not only 
by peptidic H-selective ligands but also by non-peptidic ligands, 
such as morphine and naloxone. 
2. Materials and methods 
2.1. Materials 
[Tyrosyl-3,5-3H(N)]DAMGO (50.5 Ci/mmol), [phenyl-3,4- 
3H]U69,593 ((+)-(5ct,7~t,8fl)-N-methyl-N-[7-(1-pyrroli dinyl)-l-oxa- 
spiro[4,5]dec-8-yl]benzeneacetamide) (52.9 Ci/rnmol) and (-)-[9- 
3H(N)]bremazocine (29.8 Ci/mmol) were purchased from DuPont-New 
England Nuclear (Boston, USA). DAMGO was purchased from Cam- 
bridge Research Biochemicals Ltd. (Cheshire, UK). Morphine hydro- 
chloride was from Takeda Chemical Industries Ltd. (Osaka, Japan). 
Naloxone hydrochloride was from Sigma Chemical Co. (St. Louis, 
USA). Dermorphin, morphiceptin and CTOP were from Peninsula 
Laboratories Inc. (Belmont, USA). 
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2.2. Construction of chimeric receptors 
The chimeric receptors between/z- and x-OPRs were constructed by 
using the intrinsic (AflIII sites in/z- and x-OPR cDNAs and BglII site 
in x-OPR cDNA) and introduced (BglII site in/~-OPR cDNA) restric- 
tion enzyme sites which exist at the corresponding positions of both 
receptor cDNAs (Fig. 1). BglII site was introduced into/~-OPR cDNA 
by in vitro site-directed mutagenesis u ing a Transformer Site-Directed 
Mutagenesis Kit (2nd ver.) (Clontech Laboratories Inc., Palo Alto, CA, 
USA). The appropriate restriction enzyme fragments of the/z- and 
x-OPRs were ligated and cloned into the HindIII-ApaI site of the 
pcDNA3 eukaryotic expression vector (Invitrogen, San Diego, CA, 
USA). The sequence of each construct was confirmed by sequencing 
analysis using Sequenase ver.2 DNA sequencing kit (United States 
Biochemical, Cleveland, USA). Each constructed chimeric receptor was 
given a name on the basis of the origins of its four extracellular do- 
mains. 
2.3. Expression of wild type and chimeric receptors and binding assay 
For transient expression of the wild type and chimeric OPRs, the 
plasmid containing each receptor cDNA was transfected toCOS-7 cells 
by the DEAE-dextran method [16]. After cultivation for 65 h, the cells 
were harvested and homogenized in 50 mM Tris (pH 7.4) containing 
10 mM MgC12 and 1 mM EDTA. After centrifugation for 20 min at 
30,000 × g, the pellet was resuspended in the same buffer and used in 
the radioligand binding assay. Binding experiments for Scatchard anal- 
yses were performed with various concentrations of [3H]DAMGO or 
[3H]bremazocine. For displacement s udies, 1 nM [3H]DAMGO or 
1 nM [3H]U69,593 and various concentrations of unlabeled opioid li- 
gands were used. Non-specific binding was determined in the presence 
of 10 mM unlabeled DAMGO, bremazocine or U69,593. Incubations 
of cell membranes with [3H]DAMGO, [3H]bremazocine or[3H]U69,593 
in the presence or absence of competing opioid ligands were carried out 
at 25°C for 1 h and terminated by the addition of ice-cold buffer and 
rapid filtration over Whatman GF/C glass fiber filters which were 
pretreated with 0. 1% polyethyleneimine. The filters were washed with 
ice-cold buffer and the radioactivity on each filter was measured by 
liquid scintillation counting. 
3. Results and discussion 
To determine which the first or latter half of the receptor is 
involved in the discrimination between /2- and ~c-OPRs by 
DAMGO,  we constructed two chimeric receptors using restric- 
tion enzyme AfllII. The chimeric receptor KKMM,  in which 
the amino-terminal half of the/2-OPR was replaced with the 
corresponding region of lc-OPR, exhibited an equivalent affin- 
ity (Ka = 4.38 _+ 0.90 nM; n = 3) to DAMGO compared with 
the wild type/2-OPR (K a -- 3.46 _ 0.84 nM; n = 3), while the 
reciprocal chimeric receptor MMKK poorly bound 
[3H]DAMGO and the Ka value could not be determined as in 
the case of the wild type x-OPR (Fig. 2). These results suggest 
that the latter half of the receptor structure is critical for 
DAMGO to distinguish between/2- and x-OPRs. Interestingly, 
this is quite the reverse of the case that the first half of the 
receptor is important to the discrimination between/2- and 
8-OPRs by DAMGO [15]. For further clarification of the re- 
gion responsible for subtype-selective binding of DAMGO,  we 
constructed two chimeric receptors using the restriction enzyme 
BgllI. The chimeric receptor KKKM,  in which the region from 
amino-terminal to the middle of the fifth transmembrane do- 
main of/2-OPR was replaced with the corresponding region of 
x-OPR, exhibited an equivalent affinity to DAMGO 
(Ka = 3.56 -+ 0.92 nM; n = 3) compared with the wild type/2- 
OPR. On the contrary, the chimeric receptor MMMK did not 
display any specific binding to [3H]DAMGO. Because all of the 
four chimeric receptors were verified to bind [3H]bremazocine, 
a non-selective opioid ligand, with high affinity (data not 
shown), the lack of [3H]DAMGO binding to chimeric receptors 
MMKK and MMMK was not due to the low expression of 
these chimeric receptors nor due to the overall alteration in 
tertiary structures of the receptors. These results indicate that 
the region around the third extracellular loop is critical for 
DAMGO to distinguish between/2- and x-OPRs. This is very 
different from the case of the discrimination between/2- and 
8-OPRs by DAMGO in which the region around the first 
extracellular loop is important. 
Next, to examine the importance of the region around the 
third extracellular loop to the discrimination between/2- and 
x-OPRs by other/2-selective opioid ligands, we carried out the 
displacement studies using/2- and x-OPRs and the chimeric 
EXTRA- 
CELLULAR 
PLASMA 
MEMBRANE 
INTRA- 
CELLULAR 
Fig. 1. Proposed model for membrane topography of the rat ,u-opioid receptor. Solid circles indicate amino acid residues conserved between/2- and 
x-opioid receptors. Noted are the unique restriction enzyme sites used to construct chimeric receptors. 
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Fig. 3. Displacements of the specific binding of [3H]DAMGO to the membrane of COS-7 cells expressing ,u- (©) or KKKM (0) receptor and of 
[3H]U69,593 to the membrane of COS-7 cells expressing x- ([5]) receptor with unlabeled/t-selective opioid ligands. 
receptor KKKM (Fig. 3). [3H]DAMGO was used to label p- 
and KKKM receptors and [3H]U69,593 to label x-OPR. K d 
values of [3H]DAMGO to / l -  and KKKM receptors and of 
[3H]U69,593 to x-OPR were nearly equivalent (3.46 + 0.84 nM 
in/.t-OPR, 3.56 + 0.92 nM in KKKM receptor and 3.02 _+ 0.41 
nM in x-OPR). Unlabeled DAMGO displaced the binding of 
the tritiated ligand to/1 and KKKM receptors in the same 
degree, while the potency of unlabeled DAMGO to inhibit the 
specific binding of the tritiated ligand to x-OPR was about 100 
times lower than those to/2 and KKKM receptors. Replace- 
ment of the region around the third extracellular loop ofx-OPR 
with the corresponding region ofp-OPR increased the affinity 
to/l-selective peptidic ligands, such as dermorphin, morph- 
iceptin and CTOP. Particularly, a/l-selective peptidic agonist 
morphiceptin showed an equivalent affinity to KKKM recep- 
tor compared with that to the wild type/z-OPR, while the 
increment in the affinity of a/l-selective peptidic antagonist 
CTOP is a little. Non-peptidic ligands, morphine and naloxone, 
also bound to KKKM receptor with higher affinity than to 
x-OPR. In particular, naloxone xhibited an equivalent affinity 
to KKKM receptor compared with that to the wild type/~- 
OPR, These results indicate that the region around the third 
extracellular loop is critical not only for p-selective peptidic 
ligands but also for non-peptidic ligands to distinguish between 
/t- and x-OPRs. This is the case quite different from that the 
replacement of the region around the first extracellular loop of 
6-OPR with the corresponding region of/z-OPR increased the 
affinity of the peptidic ligands, such as DAMGO, dermorphin 
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and morphiceptin, but not of the non-peptidic ligands, such as 
morphine and naloxone [15]. To further elucidate the contribu- 
tion of the region around the third extracellular loop to the 
binding selectivity of the non-peptidic ligands, we should exam- 
ine the effect of replacement of such a region between/1- and 
~-OPRs on the affinity of those ligands. 
A 'message and address' concept for opioid ligands has been 
proposed by Portoghese [17]. Briefly, the concept is that the 
specific regions of opioid ligands are responsible for receptor 
transduction process that leads to a specific biological effect 
('message'), while other ligand regions provide additional bind- 
ing affinity and are not essential for the transduction process 
('address'). This idea has been supported by a recent molecular 
pharmacological study using H/x chimeric receptors reported 
by Wang et al. [18]. They revealed that substitution of the 
second extracellular loop of/ I-OPR for the corresponding re- 
gion of x-OPR increased the affinity for dynorphin A [1-17] by 
about 100-fold. In this study, we demonstrated that DAMGO 
distinguished between/1- and x-OPRs at the different region 
from that for the distinction between/1- and 6-OPRs. These 
findings suggest hat at least two specific regions of DAMGO 
play a role of 'address' for selective binding to H-OPR. One 
region is responsible for the interaction with the receptor do- 
main around the first extracellular loop and critical in the 
distinction between ,u- and ~-OPRs. The other interacts with 
the domain around the third extracellular loop to play an im- 
portant role in the discrimination between/1- and x-OPRs. The 
interactions between the receptor and DAMGO in such do- 
mains of/ l- ,  but not ~- nor x-, OPR may provide additional 
binding affinity to produce the high affinity binding of 
DAMGO to/I-OPR. Alternatively, the interactions may 'nega- 
tively' act on the binding of DAMGO to ~- and x-OPRs, that 
is, the domain around the first extracellular loop of ~-OPR and 
that around the third extracellular loop of x-OPR may hinder 
the binding of DAMGO to these OPRs, respectively. Further 
studies are necessary to clarify the molecular basis for high 
selectivity of DAMGO to p-OPR. 
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